Development of Special Biological Products.
Annual progress rept. 1 Jan-31 Dec 81,
SALK INST SWIFTWATER PA GOVERNMENT SERVICES DIV
Pagination or Media Count:
Tissue Culture Two production lots of FRhL-2 and one of MRC-5 were stabilized and frozen this year. A new production seed for MRC-5 was processed at Pass 14. VEE C-84 Vaccine Development One lot of vaccine C-84-7 was prepared this year to satisfy the volume requirement. VEE Vaccine Potency Testing Lots C-84-1, C-84-1A MNLBR 109, C-84-2 Run 1 and C-84-3 Run 1 TSI-GSD 205 of VEE vaccine were potency tested in guinea pigs by HI and protection and challenge. A comparison of the challenge virus titrated in guinea pigs vs the mouse gave identical LD50 titers. WEE Vaccine Development Three WEE virus isolates were evaluated for vaccine antigens. Tissue culture passages in primary CEC of these viruses did not produce potent vaccines, however, one of the viruses produced potent inactivated vaccine following one passage in chicken embryos. The egg passage seed virus was used to produce a 25-liter lot of vaccine. This vaccine has been shown to be a safe, potent, inactivated preparation. Rift Valley Fever Vaccine WRAIR Potency Testing Lots 18 and 19 of Rift Valley Fever Vaccine prepared during June 1964 at WRAIR were potency tested in accordance with instructions contained in the 26 March 1981 letter from WRAIR.
- Medicine and Medical Research